ArticleFrontiers in oncology2026
Aerobic exercise training attenuates the deleterious effects of walker-256 cancer: effects on physical capacity, cachexia, and cardiac mass.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aerobic exercise training (AET) is widely recognized for its preventive and therapeutic efficacy in chronic non-communicable diseases. Although studies have shown that AET delays tumor growth and cachexia in Walker-256 tumor-bearing rats, little is known about the impact of AET on cardiac phenotypes in different cancer models. Therefore, the aim of this study was to investigate cancer cachexia-induced cardiac changes in Walker-256 tumor and to analyze the therapeutic effects of AET on these changes. Methods: Wistar (n= 24) male rats were assigned into 3 groups: Wistar control (WC), control tumor (WCT), and tumor trained (WTT). Walker-256 tumor cells were subcutaneously injected into cancer groups to establish a robust cancer cachexia model. Swimming exercise training lasted 60 min, 5×/week/6 weeks, with 5% body weight workload. We assessed: exercise tolerance, hemodynamic parameters, tumor growth and cachexia, skeletal muscle and left ventricular mass by ratio of tissue weight/tibia length. Cardiac morphology and function were evaluated by echocardiography. Results: Walker-256 tumor induced exercise intolerance in the WCT group (267.65 ± 53.55 m; p < 0.05) compared to the WC group (455.77 ± 50.22 m). In contrast, AET prevented the exercise intolerance in the WTT group (578.63 ± 66.84 m) compared to control. WTT group showed a reduction in tumor weight (25.08 ± 4.05 g; p < 0.001) and the percentage of cachexia (7.83 ± 1.75%; p < 0.05) compared to the WCT group (47.08 ± 6 g/13.75 ± 1.71%), indicating a greater evolution of tumor growth and body weight loss in relation to trained group. Skeletal muscle wasting (soleus, gastrocnemius, plantaris and tibial anterior) was observed in cancer cachexia compared to control. In this way, Walker-256 tumor exhibited cardiac remodeling characterized by cardiac atrophy. AET reversed soleus and plantaris atrophy and led to significant anti-cardiac remodeling evaluated by LV mass in Walker-256 tumor. Conclusion: Our data provides a robust model of cancer cachexia, as well as highlights the effects of AET as a preventive strategy for mitigating the exercise intolerance, tumor growth, cachectic status, and the cardiac damage in Walker- 256 tumor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.